470 related articles for article (PubMed ID: 24923038)
1. [Treatment of hepatitis C: current status and perspectives].
Pol S; Corouge M
Rev Prat; 2014 May; 64(5):605-12. PubMed ID: 24923038
[TBL] [Abstract][Full Text] [Related]
2. [Hepatitis C virus: 25 years-old, the end?].
Pol S
Med Sci (Paris); 2013 Nov; 29(11):998-1003. PubMed ID: 24280503
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hepatitis C: perspectives.
Pol S; Corouge M
Med Mal Infect; 2014 Oct; 44(10):449-54. PubMed ID: 25174659
[TBL] [Abstract][Full Text] [Related]
4. Rapid progression of antiviral treatments of chronic hepatitis C virus infection.
Pol S; Corouge M; Mallet V; Sogni P
Minerva Gastroenterol Dietol; 2013 Jun; 59(2):161-72. PubMed ID: 23831907
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
6. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.
Wyles DL; Gutierrez JA
J Viral Hepat; 2014 Apr; 21(4):229-40. PubMed ID: 24597691
[TBL] [Abstract][Full Text] [Related]
7. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z;
Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hepatitis C virus genotype 3-infection.
Pol S; Vallet-Pichard A; Corouge M
Liver Int; 2014 Feb; 34 Suppl 1():18-23. PubMed ID: 24373074
[TBL] [Abstract][Full Text] [Related]
10. [Direct antiviral treatment strategies in chronic hepatitis C].
Neumann-Haefelin C; Blum HE; Thimme R
Dtsch Med Wochenschr; 2012 Jun; 137(25-26):1360-5. PubMed ID: 22653493
[TBL] [Abstract][Full Text] [Related]
11. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Asselah T; Marcellin P
Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
[TBL] [Abstract][Full Text] [Related]
12. New developments in HCV therapy.
Kronenberger B; Zeuzem S
J Viral Hepat; 2012 Jan; 19 Suppl 1():48-51. PubMed ID: 22233414
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
[TBL] [Abstract][Full Text] [Related]
14. A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus.
Taieb V; Pacou M; Ho S; Pettré S; Van Sanden S; Pisini M; Ustianowski A; Mehnert A
J Med Econ; 2015; 18(10):787-96. PubMed ID: 25934147
[TBL] [Abstract][Full Text] [Related]
15. Preparation of HCV infected patients to the triple therapy with first generation protease inhibitors.
Kozielewicz D; Halota W; Dybowska D
Przegl Epidemiol; 2013; 67(4):623-8,713-6. PubMed ID: 24741907
[TBL] [Abstract][Full Text] [Related]
16. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
Matthews SJ; Lancaster JW
Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C therapy in non-genotype 1 patients: the near future.
Wartelle-Bladou C; Le Folgoc G; Bourlière M; Lecomte L
J Viral Hepat; 2012 Aug; 19(8):525-36. PubMed ID: 22762136
[TBL] [Abstract][Full Text] [Related]
18. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
Butt AA; Kanwal F
Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
[TBL] [Abstract][Full Text] [Related]
19. Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.
Sultanik P; Mallet V; Lagaye S; Casrouge A; Dorival C; Barthe Y; Fontaine H; Hézode C; Mottez E; Bronowicki JP; Carrat F; Theodorou I; Abel L; Gayat E; Fontanet A; Pol S; Albert ML;
Liver Int; 2015 Jul; 35(7):1833-44. PubMed ID: 25556540
[TBL] [Abstract][Full Text] [Related]
20. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
Trembling PM; Tanwar S; Dusheiko GM
Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]